Would you offer systemic therapy for BCLC Stage C HCC (portal vein invasion) following local therapy with Y90?

Has the recent approval of atezolizumab/bevacizumab impacted your decision making?

Answer from: Medical Oncologist at Academic Institution

BCLC stage C HCC includes patients with advanced diseases with symptoms and/or invasive pattern by vascular invasion or extrahepatic spread. These patients are eligible for palliative treatments including systemic therapy in a standard of care setting or clinical trial.For consideration of systemic ...

Comments

Medical Oncologist at Thomas Jefferson University Hospital
Overall, I agree with @Nguyen H. Tran. I think if ...

Medical Oncologist at Los Angeles VA Medical Center
Thank you @Nguyen H. Tran and @Daniel Lin for your...

Please select the option that best describes you:

Would you offer systemic therapy for BCLC Stage C HCC (portal vein invasion) following local therapy with Y90?

Related Questions